Exhibit 99.1
FOR IMMEDIATE RELEASE
Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with
Year over Year Product Revenue Growth of 46%
| · | Product revenue up 12% compared to September 2017 quarter |
| · | U.S. product revenue up 27% compared to the September 2017 quarter |
| · | Cash on hand equals $8.6 million at quarter end |
Conference Call Begins at 4:30pm EST Today
Slide Presentation to Review in Tandem with Earnings Call Available at http://ir.sonomapharma.com/events.cfm
PETALUMA, Calif.—(February 7, 2018)— Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced financial results for the third quarter of fiscal year 2018, ended December 31, 2017.
Total revenue was $4.8 million for the third quarter as compared to $3.4 million for the same period last year. Product revenues of $4.6 million were up 46%, or $1.5 million, when compared to the same period last year, as result of strong growth in the United States, Europe, and Latin America.
“This quarter’s revenue of $4.8 million is our highest quarterly revenue in the history of the company. This record revenue has been driven by robust year-over-year and quarter-over-quarter growth in the prescription dermatology business – our primary focus over the last three years. These results include sales growth in our Levicyn, Celacyn, Ceramax, SebuDerm and Mondoxyne products,” said Jim Schutz, Sonoma Pharmceuticals CEO.
Business Highlights
| · | Robust portfolio of six non-steroidal products for treatment of atopic and seborrheic dermatitis, surgical procedures, severe acne, skin repair, descaling, and scar management. |
| · | Company has 30 sales representatives and five sales managers, focused exclusively on the dermatology prescription market. |
| · | Received approval by Brazilian Ministério da Saúde for seven non-steroidal and non-antibiotic, topical dermatology products in October 2017. |
| · | Received approval from United Arab Emirates (UAE) Ministry of Health & Prevention of three products for daily eyelid hygiene, antimicrobial nasal cleaning and antiseptic mouth and throat rinse. |
| · | Received two FDA clearances to add antimicrobial language to both AlevicynSG™ Spray Gel and Alevicyn™ Dermal Spray solution. |
Results for the Three months Ended December 31, 2017
Product revenues in the United States, of $2.9 million, for the three months ended December 31, 2017, increased by $1.2 million, or 73%, as compared to $1.7 million for the three months ended December 31, 2016. This increase was mostly the result of higher sales of the company’s dermatology, acute care and animal health care products.
Product revenue in Latin America for the quarter ended December 31, 2017, was $772,000. This amount reflects the sale of products to Invekra, following the completion of Sonoma’s asset sale to Invekra in October 2016. Sonoma will continue to supply products to Invekra until its manufacturing facility is operational.
Product revenue in Europe and the rest of the world of $992,000, for the three months ended December 31, 2017, decreased by $46,000, or 4%, as compared to $1.0 million for the three months ended December 31, 2016. This decrease was the result of lower sales in China and the Middle East, mostly offset by higher sales in Europe, Singapore, Hong Kong and India.
| 1 |
Sonoma reported gross profit of $2.4 million, or 49% of total revenue, during the three months ended December 31, 2017, compared to a gross profit of $1.7 million, or 51% of total revenue in the same period in the prior year. The decrease in gross profit, as a percentage of revenue, was primarily due to the lower profitability in Latin America related to the higher sales to Invekra at a very low profit, partly offset by higher margins in the United States caused by the strong growth of the more profitable dermatology product lines.
Operating expenses minus non-cash expenses during the third quarter of fiscal year 2018 were $4.9 million, up $555,000, or 13%, as compared to the same period in the prior year. This increase in operating expenses was mostly due to higher sales, marketing and administrative expenses in the United States related to the growth of a direct sales force in dermatology, partly offset by a decline in Latin American expenses. A key driver to the growth in operating expenses is the increase in the number of sales representatives, compared to the same period last year.
Loss from operations was $3.2 million, down $365,000, compared to $3.6 million for the same period last year. Operating loss less non-cash expenses (EBITDA) for the three months ended December 31, 2017, was $2.4 million, compared to $2.5 million for the same period last year.
As of December 31, 2017, Sonoma had cash and cash equivalents of $8.6 million, as compared to $10 million as of September 30, 2017.
Results for the Nine Months Ended December 31, 2017
Total revenues of $13 million increased by $4.2 million, or 48%, for the nine months ended December 31, 2017, as compared to $8.8 million for the nine months ended December 31, 2016. Product revenue of $12.4 million for the nine months ended December 31, 2017, increased $4.2 million, or 52%, compared to the same period last year. This increase in product revenue was driven by strong growth in the United States, up $2.3 million, or 48% and by higher sales in Europe and rest of world, up $337,000, or 11%.
The company reported gross profit related to sales of its products of $6.0 million, or 46% of total revenues, for the nine months ended December 31, 2017.
Total operating expenses less non-cash expenses of $13.8 million increased $1.7 million, or 14%, for the nine months end December 31, 2017, as compared to the same period in the prior year. This increase was primarily due to higher costs of the direct sales force for dermatology. Operating loss less non-cash expenses (EBITDA) of $7.5 million, for the nine months ended December 31, 2017, was down $572,000, compared to $8.1 million for the same period last year.
Conference Call
Sonoma’s management will hold a conference call today to discuss third quarter fiscal year 2018 results and answer questions, beginning at 4:30 p.m. EST. Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those interested in listening to the conference call live via the Internet may do so at http://ir.sonomapharma.com/events.cfm . Please log on approximately 30 minutes prior to the presentation in order to register and download the appropriate software. Also, participants can download a graphical presentation of the quarterly results at this same site, which can provide greater granular detail in conjunction with the call.
A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 5949729. A webcast replay will be available on the site at http://ir.sonomapharma.com/events.cfm for one year following the call.
Sale of Latin American Business and Impact on Accounting Treatment
With the sale of the Latin American business during the third quarter ended December 31, 2016, the components of the financial statements related to this transaction have been classified as a discontinued business for accounting purposes and in accordance with this accounting treatment, the income statement and balance sheet have been retroactively revised to reflect the revenue, expenses and balance sheet items of the continuing businesses for this fiscal year and last fiscal year. All of the income statement categories related to Latin America have been condensed to a one line item on the income statement as “Income from discontinued operations.” Also, the discontinued balance sheets items have been listed separately from the continuing operations. As a result, the comparison of results discussed in this press release relate primarily to the continuing businesses in accordance with generally accepted accounting principles.
About Sonoma Pharmaceuticals, Inc.
Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.
| 2 |
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company’s cash needs, fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Alevicyn™, Celacyn™, SebuDerm™ and Microcyn® Technology are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@sonomapharma.com
| 3 |
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | March 31, | |||||||
| 2017 | 2017 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 8,625 | $ | 17,461 | ||||
| Accounts receivable, net | 2,609 | 2,108 | ||||||
| Inventories, net | 2,701 | 2,221 | ||||||
| Prepaid expenses and other current assets | 1,508 | 616 | ||||||
| Current portion of deferred consideration, net of discount | 229 | 237 | ||||||
| Total current assets | 15,672 | 22,643 | ||||||
| Property and equipment, net | 1,200 | 1,239 | ||||||
| Deferred consideration, net of discount, less current portion | 1,392 | 1,497 | ||||||
| Other assets | 91 | 80 | ||||||
| Total assets | $ | 18,355 | $ | 25,459 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,400 | $ | 1,255 | ||||
| Accrued expenses and other current liabilities | 1,515 | 1,302 | ||||||
| Deferred revenue | 180 | 345 | ||||||
| Deferred revenue Invekra | 140 | 176 | ||||||
| Current portion of long-term debt | 12 | 123 | ||||||
| Current portion of capital leases | 146 | 74 | ||||||
| Taxes payable | – | 13 | ||||||
| Total current liabilities | 3,393 | 3,288 | ||||||
| Long-term deferred revenue Invekra | 492 | 527 | ||||||
| Long-term debt, less current portion | 35 | 45 | ||||||
| Long-term capital leases, less current portion | 179 | 168 | ||||||
| Total liabilities | 4,099 | 4,028 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders’ Equity | ||||||||
| Convertible preferred stock, $0.0001 par value; 714,286 shares authorized, none issued and outstanding at December 31, 2017 and March 31, 2017, respectively | – | – | ||||||
| Common stock, $0.0001 par value; 12,000,000 shares authorized at December 31, 2017 and March 31, 2017, 4,637,541 and 4,289,322 shares issued and outstanding at December 31, 2017 and March 31, 2017, respectively | 1 | 1 | ||||||
| Additional paid-in capital | 171,332 | 168,709 | ||||||
| Accumulated deficit | (152,677 | ) | (143,101 | ) | ||||
| Accumulated other comprehensive loss | (4,400 | ) | (4,178 | ) | ||||
| Total stockholders’ equity | 14,256 | 21,431 | ||||||
| Total liabilities and stockholders’ equity | $ | 18,355 | $ | 25,459 | ||||
| 4 |
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive (Loss) Income
(In thousands, except per share amounts)
(Unaudited)
|
Three Months Ended
December 31, |
Nine Months Ended
December 31, |
|||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenues | ||||||||||||||||
| Product | $ | 4,647 | $ | 3,174 | $ | 12,394 | $ | 8,158 | ||||||||
| Service | 196 | 187 | 609 | 638 | ||||||||||||
| Total revenues | 4,843 | 3,361 | 13,003 | 8,796 | ||||||||||||
| Cost of revenues | ||||||||||||||||
| Product | 2,308 | 1,476 | 6,529 | 4,507 | ||||||||||||
| Service | 167 | 179 | 496 | 568 | ||||||||||||
| Total cost of revenues | 2,475 | 1,655 | 7,025 | 5,075 | ||||||||||||
| Gross profit | 2,368 | 1,706 | 5,978 | 3,721 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 349 | 487 | 1,099 | 1,226 | ||||||||||||
| Selling, general and administrative | 5,219 | 4,784 | 14,319 | 12,557 | ||||||||||||
| Total operating expenses | 5,568 | 5,271 | 15,418 | 13,783 | ||||||||||||
| Loss from operations | (3,200 | ) | (3,565 | ) | (9,440 | ) | (10,062 | ) | ||||||||
| Interest expense | (11 | ) | – | (31 | ) | (2 | ) | |||||||||
| Interest income | 14 | 6 | 85 | 8 | ||||||||||||
| Other income (expense), net | 10 | 282 | (179 | ) | 276 | |||||||||||
| Net loss from continuing operations before income taxes | (3,187 | ) | (3,277 | ) | (9,565 | ) | (9,780 | ) | ||||||||
| Tax benefit | – | 4,040 | – | 4,040 | ||||||||||||
| Net (loss) income from continuing operations | (3,187 | ) | 763 | (9,565 | ) | (5,740 | ) | |||||||||
| Net income from discontinued operations (net of tax) | – | 15,465 | – | 17,450 | ||||||||||||
| Net (loss) income | $ | (3,187 | ) | $ | 16,228 | $ | (9,565 | ) | $ | 11,710 | ||||||
| Net (loss) income per share: basic | ||||||||||||||||
| Continuing operations | $ | (0.73 | ) | $ | 0.18 | $ | (2.21 | ) | $ | (1.36 | ) | |||||
| Discontinued operations | – | 3.66 | – | 4.15 | ||||||||||||
| $ | (0.73 | ) | $ | 3.84 | $ | (2.21 | ) | $ | 2.79 | |||||||
| Weighted-average number of shares used in per share calculations: basic | 4,392 | 4,225 | 4,333 | 4,209 | ||||||||||||
| Net (loss) income per share: diluted | ||||||||||||||||
| Continuing operations | $ | (0.73 | ) | $ | 0.18 | $ | (2.21 | ) | $ | (1.36 | ) | |||||
| Discontinued operations | – | 3.66 | – | 4.15 | ||||||||||||
| $ | (0.73 | ) | $ | 3.84 | $ | (2.21 | ) | $ | 2.79 | |||||||
| Weighted-average number of shares used in per share calculations: diluted | 4,392 | 4,228 | 4,333 | 4,209 | ||||||||||||
| Other comprehensive (loss) income | ||||||||||||||||
| Net (loss) income | $ | (3,187 | ) | $ | 16,228 | $ | (9,565 | ) | $ | 11,710 | ||||||
| Foreign currency translation adjustments | (377 | ) | (416 | ) | (222 | ) | (817 | ) | ||||||||
| Comprehensive (loss) income | $ | (3,564 | ) | $ | 15,812 | $ | (9,787 | ) | $ | 10,893 | ||||||
| 5 |
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
Reconciliation of GAAP measures to non-GAAP measures
(In thousands) and (Unaudited)
|
Three Months Ended
December 31, |
Nine Months Ended
December 31, |
|||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| (1) Loss from operations minus non-cash expenses (EBITDA): | ||||||||||||||||
| GAAP loss from operations as reported | $ | (3,200 | ) | $ | (3,565 | ) | $ | (9,440 | ) | $ | (10,062 | ) | ||||
| Non-cash adjustments: | ||||||||||||||||
| Stock-based compensation | 692 | 1,013 | 1,592 | 1,830 | ||||||||||||
| Depreciation and amortization | 125 | 60 | 366 | 178 | ||||||||||||
| Non-GAAP loss from operations minus non-cash expenses (EBITDA) | $ | (2,383 | ) | $ | (2,492 | ) | $ | (7,482 | ) | $ | (8,054 | ) | ||||
| (2) Net loss minus non-cash expenses: | ||||||||||||||||
| GAAP net income (loss) as reported | $ | (3,187 | ) | $ | 16,228 | $ | (9,565 | ) | $ | 11,710 | ||||||
| Non-cash adjustments: | ||||||||||||||||
| Stock-based compensation | 692 | 1,013 | 1,592 | 1,830 | ||||||||||||
| Depreciation and amortization | 125 | 60 | 366 | 178 | ||||||||||||
| Non-GAAP net income (loss) minus non-cash expenses | $ | (2,370 | ) | $ | 17,301 | $ | (7,607 | ) | $ | 13,718 | ||||||
| (3) Operating expenses minus non-cash expenses | ||||||||||||||||
| GAAP operating expenses as reported | $ | 5,568 | $ | 5,271 | $ | 15,418 | $ | 13,783 | ||||||||
| Non-cash adjustments: | ||||||||||||||||
| Stock-based compensation | (649 | ) | (950 | ) | (1,456 | ) | (1,633 | ) | ||||||||
| Depreciation and amortization | (57 | ) | (14 | ) | (154 | ) | (30 | ) | ||||||||
| Non-GAAP operating expenses minus non-cash expenses | $ | 4,862 | $ | 4,307 | $ | 13,808 | $ | 12,120 | ||||||||
| (1) | Loss from operations minus non-cash expenses (EBITDAS) is a non-GAAP financial measure. The Company defines operating loss minus non-cash expenses as GAAP reported operating loss minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of modifying the operating loss to reflect direct cash related transactions during the measurement period. |
| (2) | Net loss minus non-cash expenses is a non-GAAP financial measure. The Company defines net loss minus non-cash expenses as GAAP reported net loss minus depreciation and amortization, stock-based compensation, and non-cash foreign exchange transaction losses. The Company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect direct cash transactions during the measurement period. |
| (3) | Operating expenses minus non-cash expenses is a non-GAAP financial measure. The Company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. |
| 6 |
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
Product related revenue schedules
(In thousands) and (Unaudited)
The following table shows the Company’s product revenues by geographic region:
|
Three months ended December 31, |
||||||||||||||||
| 2017 | 2016 | $ Change | % Change | |||||||||||||
| United States | $ | 2,883 | $ | 1,671 | $ | 1,212 | 73% | |||||||||
| Latin America | 772 | 465 | 307 | 66% | ||||||||||||
| Europe and Rest of the World | 992 | 1,038 | (46 | ) | (4% | ) | ||||||||||
| Total | $ | 4,647 | $ | 3,174 | $ | 1,473 | 46% | |||||||||
|
Nine months ended
December 31, |
||||||||||||||||
| 2017 | 2016 | $ Change | % Change | |||||||||||||
| United States | $ | 7,010 | $ | 4,741 | $ | 2,269 | 48% | |||||||||
| Latin America | 2,095 | 465 | 1,630 | 351% | ||||||||||||
| Europe and Rest of the World | 3,289 | 2,952 | 337 | 11% | ||||||||||||
| Total | $ | 12,394 | $ | 8,158 | $ | 4,236 | 52% | |||||||||
In connection with the Company’s sale of its Latin America business to Invekra, product related revenues were reclassified from continuing operations to discontinued operations. The amounts were classified in the prior periods as Latin America sales. The amounts reclassified are as follows:
| Three Months Ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Product revenues | $ | – | $ | 359 | ||||
| Product license fees and royalties | – | 262 | ||||||
| Total product related revenues | $ | – | $ | 621 | ||||
| Nine Months Ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Product revenues | $ | – | $ | 2,693 | ||||
| Product license fees and royalties | – | 412 | ||||||
| Total product related revenues | $ | – | $ | 3,105 | ||||
| 7 |
